Drug Profile
Research programme: cord blood stem cell therapies - Saneron CCEL Therapeutics
Alternative Names: hUCB stem cell therapies - Saneron CCEL Therapeutics; Human umbilical cord blood stem cell therapies - Saneron CCEL Therapeutics; U-CORD-CELL™Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Saneron CCEL Therapeutics
- Developer Saneron CCEL Therapeutics; University of South Florida
- Class Stem cell therapies
- Mechanism of Action Alpha N acetyl D glucosaminidase replacements; Amyloid beta-protein inhibitors; Cell replacements; Nerve growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease; Amyotrophic lateral sclerosis; Mucopolysaccharidosis III; Myocardial infarction; Stroke
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (IV, Infusion)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA (IV, Injection)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Mucopolysaccharidosis-III in USA (IV, Injection)